Akrihin Comfoderm M2 cream for external use 0.1% + 2% tube 10g

Release form

Cream for external use

Packaging

Tube 30 g

pharmachologic effect

A drug with anti-inflammatory and keratolytic action for external use.

Indications

Inflammatory skin diseases sensitive to therapy with topical glucocorticosteroids and accompanied by impaired keratinization:

- atopic dermatitis, neurodermatitis

- true eczema

- microbial eczema

- simple contact dermatitis

- allergic (contact) dermatitis

- dyshidrotic eczema.

Contraindications

- hypersensitivity to drug components

- tuberculous or syphilitic processes in the area of ​​drug application

- viral diseases (for example, chickenpox, shingles)

- rosacea, perioral dermatitis in the area of ​​application of the drug

- skin areas with manifestations of a reaction to vaccination

- children under 18 years of age.

special instructions

In the presence of bacterial complications and / or dermatomycosis, in addition to therapy with Comfoderm M2, specific antibacterial and / or antifungal treatment should be carried out.

The drug is not intended for use in ophthalmology.

Avoid contact with the eyes and mucous membranes.

As with the use of systemic glucocorticoids, with external use of GCS, glaucoma may develop (for example, after use in high doses, due to very long use, the use of occlusive dressings or application to the skin around the eyes).

On the skin of the face more often than on other surfaces of the body, after prolonged treatment with GCS for external use, atrophic changes may develop.

Influence on the ability to drive vehicles and use mechanisms

Not found.

Structure

100 g of cream contains:

Active substances: methylprednisolone aceponate 100 mg

urea 2 g

Excipients: liquid paraffin (vaseline oil) - 15 g, propylene glycol - 5 g, polysorbate 80 - 1 g, carbomer interpolymer (type A) - 1 g, trometamol - 400 mg, methyl parahydroxybenzoate - 100 mg, purified water - up to 100 g ...

Method of administration and dosage

Outwardly.

The drug is applied 1 time / day in a thin layer to the affected skin.

As a rule, the duration of continuous daily treatment with Comfoderm M2 should not exceed 12 weeks.

When treating patients with facial skin lesions, the course of treatment should not exceed 5 days.

Side effects

Very rarely (less than 0.01% of cases), local reactions can occur, such as itching, burning, erythema, and vesicular rash.

If the drug is used for more than 4 weeks and / or on an area of ​​10% or more of the body surface, the following reactions may occur: skin atrophy, telangiectasia, striae, acneform skin changes, systemic effects due to the absorption of corticosteroid.

In rare cases (0.01% -0.1%), folliculitis, hypertrichosis, perioral dermatitis, skin depigmentation, allergic reactions to one of the drug components may occur.

Drug interactions

The interaction of the drug with other drugs has not been identified, however, it should be borne in mind that the simultaneous use of the drug Comfoderm M2 with other ointments or creams can lead to an increase in the resorption of their constituent drugs.

Overdose

Symptoms: with excessively long and / or intensive local use of GCS, skin atrophy (thinning of the skin, telangiectasia, striae) may develop.

Treatment: if signs of skin atrophy appear, the drug must be canceled.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C.

Shelf life

2 years

Active substance

Methylprednisolone aceponate, Urea

Name ENG

KOMFODERM M2

Clinical and pharmacological group

Preparation with anti-inflammatory and moisturizing action for external use

ATX code

highly active orticosteroids in combination with other drugs

Dosage

0.1% + 2% x 10g

Structure

100 g of cream contains: Active ingredients: methylprednisolone aceponate 100 mg

urea 2 g Excipients: liquid paraffin (vaseline oil) - 15 g, propylene glycol - 5 g, polysorbate 80 - 1 g, carbomer interpolymer (type A) - 1 g, trometamol - 400 mg, methyl parahydroxybenzoate - 100 mg, purified water - up to 100 g.

Indications

Inflammatory skin diseases that are sensitive to therapy with topical glucocorticosteroids and are accompanied by impaired keratinization: atopic dermatitis, neurodermatitis

true eczema

microbial eczema

simple contact dermatitis

allergic (contact) dermatitis

dyshidrotic eczema.

Contraindications

Hypersensitivity to drug components

tuberculous or syphilitic processes in the area of ​​application of the drug

viral diseases (for example, chickenpox, shingles)

rosacea, perioral dermatitis in the area of ​​application of the drug

areas of the skin with manifestations of a reaction to vaccination

children under 18 years of age.

INN / Active ingredient

Methylprednisolone aceponate, Urea

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 2 years

Specifications

Category

Regenerating agents

Scope of the drug

Dermatology

Release form

Cream

Manufacturer country

Russia

Package quantity, pcs

one

Scope of application

Dermatology

,

Allergology

Minimum age from

18 years

Way of introduction

Locally

,

Outwardly

Vacation conditions

Without recipe

Brand name

Akrikhin

The amount of the dosage form in the primary package

10 g

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Dosage form

Cream for external use

The target audience

Adult

Expiration date in days

730

Dosage (volume) of the substance in the preparation

100 g: methylprednisolone aceponate 0.1 g, urea 2 g

Package weight, g

twenty

Mode of application

:

Outwardly. < br> The drug is applied 1 time / day with a thin layer on the affected skin.

As a rule, the duration of continuous daily treatment with Comfoderm M2 should not exceed 12 weeks.

When treating patients with facial skin lesions, the course of treatment should not exceed 5 days.

Pharmaco-therapeutic group

:

Topical glucocorticosteroid + keratolytic agent

Anatomical and therapeutic characteristics

:

D07XC Active glucocorticosteroids, in combination with other drugs

Information on technical characteristics, delivery set, country of manufacture